Starpharma Holdings Ltd (ASX: SPL, OTCQX: SPHRY) today announced completion of its international, multicentre, phase 3 clinical studies evaluating VivaGel^® BV for the prevention of recurrent bacterial vaginosis (rBV). Starpharma expects topline results of the trials to be available in the second quarter of 2017.

Starpharma released its interim report and financial results for the half-year ended 31 December 2016.

Financial Summary

• Reported loss of $9.0M (Dec 2015: $10.0M)
• R&D tax incentives of $1.7M reported in the half-year (Dec 2015: $1.8M)
• Cash position at 31 December 2016 of $36.3M (June 2016: $46.0M)
• Receipt of $3.5M R&D tax incentive refund from FY16

Starpharma released its Appendix 4C – Quarterly Cashflow report for the period ended 31 December 2016.

In this issue:

›› Enrolment completed for phase 3 program: VivaGel^® BV for prevention of recurrence

›› VivaGel^® BV granted QIDP and Fast Track designation by US FDA

›› Favourable revision to FDA guidance for BV Treatment

›› VivaGel^® condom approved in Canada; licensed in China and Iran

›› New DEP^® partnered programs with AstraZeneca and world leading antibody-drug conjugate companies

›› DEP^® docetaxel phase 1 program in final expansion phase; preparations underway for phase 2

›› DEP^® cabazitaxel shows no neutropenia

›› DEP^® irinotecan internal program shows superior performance

Download: Shareholder January 2017 (pdf file, 751kb)

The Australian reports that Bell Potter sees further upside for Starpharma, setting its share price target at $1.05, given the company had been granted Qualified Infectious Disease Product (QIDP) and fast track designation for VivaGel® BV by the US Food and Drug Administration.

 Go to the article (external link)

Starpharma Holdings Ltd (ASX: SPL, OTCQX: SPHRY) today announced it has been granted Qualified Infectious Disease Product (QIDP) and Fast Track designation for VivaGel^® BV by the US Food and Drug Administration (FDA).

Starpharma Holdings Ltd today announced it has received the anticipated $3.5M of R&D tax incentive refund related to FY16 expenditures. 

Chairman’s address and the CEO’s presentation to the 2016 Annual General Meeting of Starpharma Holdings Limited (ASX: SPL, OTCQX: SPHRY).

Starpharma Holdings Ltd today announced the signing of a License and Supply Agreement with Koushan Pharmed for the sales and marketing rights to the VivaGel^® condom in Iran.

Starpharma will be presenting at the Bio-Europe^® conference held in Cologne, Germany this week. At the conference Starpharma will also be conducting licensing discussions for DEP™ and VivaGel^® with pharmaceutical companies.